Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
HHS-OIG
OIG Plans Review of FDA’s Regulatory Activity, According to New Work Plan
OIG Plans to Focus on How FDA Inspects Generic Manufacturers and Enforces Postmarketing and Clinical Trial Transparency…
OIG Issues 2015 Work Plan
The Department of Health and Human Services Office of Inspector General recently released its 2015 Work Plan. OIG’s…
DaVita Reaches $350 Million Settlement Over Dialysis Center Referrals
DaVita, a leading dialysis services provider, has agreed to one of the largest healthcare settlements of 2014. The Department of…
OIG Releases Annual “Top Management and Performance Challenges” Facing the…
Yesterday, the Office of Inspector General released their annual summary of the most significant management and…
Shire Pharmaceuticals Settles for $56.5 Million to Resolve False Claims…
The Justice Department announced last week that pharmaceutical company Shire Pharmaceuticals LLC will pay $56.5 million to…
Anti-Kickback Alert: Pharmaceutical Manufacturer Copayment Coupons and…
Pharmaceutical manufacturers routinely offer copayment coupons to reduce or eliminate the cost of patients'…
OIG Releases Special Fraud Alert: Laboratory Payments to Referring…
Many physicians and other healthcare providers refer a high volume of patient specimens to third party clinical…
New Enforcement Frontier? Medtronic Settles Medical Device Kickback Case…
A number of government attorneys have spoken at compliance conferences over the last year and noted that the days of…
HHS-OIG Releases Updated Advisory on Independent Charity Patient Assistance…
Back in 2005, OIG concluded that pharmaceutical manufacturer patient assistance programs (PAPs) that subsidize Part D…
Supreme Court Declines to Review Important False Claims Act Issue
In our February article, Will Sunshine Data Help Qui Tam Whistleblowers and Their Attorneys?, we mentioned that while…